News
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going… […]
genetics
News
Opinion: Where are the guidelines for the production of animals with intentional genomic alterations?
Realizing the benefits of animals with intentional genomic alterations depends on gaining consumers’ trust, which in turn requires a regulatory system that consumers can count on. […]
News
STAT+: Bay Area biotech uses AI to unlock RNA structures — and find new therapies in the process
A new Bay Area biotech is harnessing artificial intelligence to better understand and predict RNA structures in hopes of developing new therapeutics. […]
News
STAT+: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’
“The industry is learning that almost unlimited access to capital, chasing testing volume and adding cost on the back end, is not sustainable,” said Invitae CEO Ken Knight. […]
News
STAT+: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
Element’s machine can now read a whole human genome for as little as $200 — the cost of a couple trips to the grocery store. […]
News
STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch
Pacific Biosciences, best known for its niche approach to DNA sequencing, announced plans to launch a product that will put the company in direct competition with Illumina. […]
